drugset
drugset / Trial / NCT00440583

The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP

NCT00440583 ↗

Phase 2 Completed 15 enrolled Mahidol University Bayer · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effective of Yt90-Zevalin therapy in patients with diffuse large B-cell lymphoma that have achieved at least an unconfirmed partial remission after 6 cycles of CHOP therapy.

Timeline

Start
2006-09
Primary completion
2011-09
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject ibritumomab tiuxetan Monoclonal antibody — —
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Background Prednisone Other / unclassified 40 mg/m2 Oral
Background Vincristine Small molecule 1.4 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma